hydroxychloroquine and mk 2206

hydroxychloroquine has been researched along with mk 2206 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Aisner, J; Bertino, JR; Doyle, LA; Gibbon, D; Goodin, S; Kaveney, AD; Lin, H; Malhotra, J; Mehnert, JM; Moss, RA; Portal, D; Spencer, K; Stein, MN; Tan, AR; White, EP	1

Trials

1 trial(s) available for hydroxychloroquine and mk 2206

Article	Year
A phase I trial of MK-2206 and hydroxychloroquine in patients with advanced solid tumors. Cancer chemotherapy and pharmacology, 2019, Volume: 84, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Dose-Response Relationship, Drug; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Female; Heterocyclic Compounds, 3-Ring; Humans; Hydroxychloroquine; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Phosphatidylinositol 3-Kinases; Protein Serine-Threonine Kinases	2019

Article

Year

A phase I trial of MK-2206 and hydroxychloroquine in patients with advanced solid tumors.

Cancer chemotherapy and pharmacology, 2019, Volume: 84, Issue:4

Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Dose-Response Relationship, Drug; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Female; Heterocyclic Compounds, 3-Ring; Humans; Hydroxychloroquine; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Phosphatidylinositol 3-Kinases; Protein Serine-Threonine Kinases

2019